• First Rounders

    October 2017

    play full podcast


    • In this episode: Stelios Papadopoulos

      Stelios Papadopoulos has been a biotech analyst, investment banker, and company founder. He's the current chairman of the board at Biogen. His conversation with Nature Biotechnology touches on his reasons for leaving Greece to come to the United States, how he made his mark in the nascent biotech analyst field, and his participation in late '60s radicalism.

About the First Rounders Podcast

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.


To subscribe for free to Nature Biotechnology's First Rounders podcast, copy and paste this URL into iTunes or your preferred media player: Nature Biotechnology Podcast rss feed.

If you would like to use part of any Nature Biotechnology podcast, please contact us at podcast@nature.com.

We welcome feedback so write to us at bioentrepreneur@us.nature.com. If you have any technical problems see the Help and FAQ section. All podcasts are © Nature Publishing Group.

Extra navigation

  • Sponsored by:

  • Archive

    • August 2017: First Rounders

      Greg Winter is the Master of Trinity College, Cambridge, and a serial entrepreneur, who co-founded Cambridge Antibody Technology. Much of his career was spent at the Medical Research Council, and his research led to humanized monoclonal antibodies. His conversation with Nature Biotechnology covers growing up in west Africa, how suffering an attack in the street led to a breakthrough in the lab, and the state of UK biotech.


    • June 2017: First Rounders

      Jan Vilcek is the co-founder, CEO and chairman of the Vilcek Foundation, and also a long-time researcher and professor at New York University's School of Medicine. His conversation with Nature Biotechnology covers his harrowing childhood in Czechoslovakia during the rise of Nazi Germany and World War II, his escape from communist Czechoslovakia through defection, and his role in the discovery of the blockbuster drug Remicade.


    • May 2017: First Rounders

      Rachel Haurwitz is co-founder, president and CEO of Caribou Biosciences. In her discussion with Nature Biotechnology, she explains what drew her into the sciences, how her father's journalism career brought their family to Austin, Texas, and how she found herself at the cutting edge of CRISPR technology.


    • See complete archive